These results not only provide evidence supporting the role of NRF2 in DDR to radiotherapy but also imply that the nuclear NRF2 expression level might serve as a biomarker for predicting the radiosensitivity of lung cancer. This evidence concerns the gene NFE2L2 and lung cancer.